Videos

Blood “SECmeres” and extracellular vesicles show promise for Alzheimer RNA biomarkers.

Specialty care approaches shared decision-making differently, and the stakes extend beyond a single symptom. The panel closes this discussion by debating whether treating agitation can shift disease trajectory itself.

With two on-label options now available, the choice between them comes down to comorbidities, psychosis, and risk. The panel also examines how long-term care rating pressures complicate that decision in practice.

Ending the REMS cut the paperwork, but reimbursement that ignores clozapine’s added care demands still keeps the drug from patients who could benefit.

Psychedelic psychiatry gains momentum as clinicians weigh evidence, safety, and stigma.

Andrew A. Nierenberg, MD, explains how the Bipolar Action Network uses shared data and improvement science to change how bipolar disorder care is delivered.

A new blood test approach analyzes RNA inside extracellular vesicles, aiming to spot Alzheimer disease earlier.

Christoph U. Correll, MD, explains how a new class of muscarinic agents lowers dopamine in specific brain regions without blocking dopamine receptors.

George Grossberg, MD, reviews how accurate the first FDA-cleared Alzheimer blood test is and which patient factors can skew its results.

Emerging blood RNA tests may analyze brain-derived exosomes to detect Alzheimer disease earlier.

A PHQ-9 score can mislead as easily as it clarifies. The panel unpacks the gap between rating-scale remission and how patients actually experience recovery, using real cases where appearances and scores diverged sharply.

Precision medicine looks different in psychiatry than in oncology. The panel discusses why personalizing MDD care starts with a complete patient history, and how clinical experience, evidence, and patient goals combine to guide treatment.

Anita Clayton, MD, explains why sexual dysfunction affects most patients with major depression and how it overlaps with anhedonia.

Led by the moderator, the panelists examine how to build a center that lasts.

Led by the moderator, the panelists examined the rewards and demands of interventional care.

Led by the moderator, the panelists discuss the legal, insurance credentialing, DEA licensure, REMS certification, and medication-acquisition steps behind opening a ketamine and esketamine practice, followed by staffing, systems, and outreach.

The expert psychiatrist examined safety as a layered process that begins with a trusting therapeutic relationship, continues with screening for medical contraindications and coordination with other clinicians, and extends to set, setting, and on-site emergency equipment.

Led by the moderator, the expert psychiatrist examined how he matches patients to each agent.

Led by the moderator, the expert psychiatrist discusses the TRANSFORM and SUSTAIN trials as the strongest evidence for esketamine and notes that the requirement for a concomitant oral antidepressant has since been lifted.

Real-world results and a personal caregiver's story build the case for starting a muscarinic agonist earlier, even at first break, rather than waiting until other options are exhausted.

A regimen that has worked for twenty years may still be leaving symptoms untreated. The panel makes the case for revisiting long-standing ADHD prescriptions in light of newer technology.

A newly approved muscarinic agonist offers a genuinely different mechanism for treating schizophrenia. The panel explains how it works and why most are choosing to add it rather than switch.

Treating ADHD only during visible hours leaves patients unprotected at the moments that matter most. The panel argues for symptom control that extends through bedtime, not just the workday.

The expert psychiatrist examined structured programs such as inpatient, partial hospitalization, and intensive outpatient care, then described how electroconvulsive therapy and transcranial magnetic stimulation work.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Explore how clinicians weigh ECT, TMS, ketamine, and vagus nerve stimulation for treatment-resistant depression—balancing speed, access, durability, and patient preference.

Before adding another medication, review the diagnosis, the symptoms being targeted, and any drugs prescribed only to offset adverse effects.

An oral glutamatergic option without the logistics of ketamine. Dr. Shirikjian walks through the trial program, the week-one separation, and the mechanism she had to unlearn to understand.

Older antidepressants did not get less effective, only less convenient. Dr. Clayton explains where tricyclics and MAOIs still belong, and when combining psychotherapy with medication outperforms either alone.

AI should take over burdensome tasks, not clinicians, and guardrails must stop decision support systems from guessing.